Low molecular weight heparin is a general term for a class of relatively low molecular weight heparin prepared by depolymerization of common heparin. It was developed in the 1970s by combining a new class of anticoagulant drugs. Compared with heparin therapy,LMWH has the advantages of high bioavailability in China, strong antithrombotic effect and less adverse behavior reaction in patients with bleeding. Therefore,LMWH has been widely applied in clinical studies.

　　Heparins Manufacturer: indication

　　Prevention of thromboembolic diseases (such as myocardial infarction, thrombophlebitis)

　　Treatment of thromboembolic diseases (venous thromboembolism of the lower extremities, DIC).

　　Prevention of blood clots during hemodialysis

　　Treatment included unstable and qualitative angina pectoris and non - Q - wave myocardial infarction

　　Heparins Manufacturer: Contraindication

　　Organ damage and risk of bleeding (peptic ulcer, hemorrhagic stroke, etc.)

　　Hypersensitivity to heparin, low molecular weight heparin and its derivatives.

　　Patients with a history of thrombocytopenia associated with low molecular weight heparin

　　Postpartum hemorrhage and severe liver and kidney dysfunction

　　Patients with severe hypertension, severe brain injury, and acute infective endocarditis.